iTeos Therapeutics, Inc. Stock price

Equities

ITOS

US46565G1040

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
13.64 USD +3.57% Intraday chart for iTeos Therapeutics, Inc. +19.65% +24.57%
Sales 2024 * 3.15M Sales 2025 * 8.12M Capitalization 472M
Net income 2024 * -164M Net income 2025 * -238M EV / Sales 2024 * 150 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 58.1 x
P/E ratio 2024 *
-2.95 x
P/E ratio 2025 *
-2.13 x
Employees 157
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.46%
More Fundamentals * Assessed data
Dynamic Chart
1 day+6.64%
1 week+18.97%
Current month+22.97%
1 month+20.05%
3 months+22.40%
6 months+14.42%
Current year+20.27%
More quotes
1 week
11.04
Extreme 11.04
13.42
1 month
10.20
Extreme 10.2
13.42
Current year
9.70
Extreme 9.7
13.42
1 year
8.20
Extreme 8.2
18.24
3 years
8.20
Extreme 8.2
52.43
5 years
8.20
Extreme 8.2
52.43
10 years
8.20
Extreme 8.2
52.43
More quotes
Managers TitleAgeSince
Founder 57 12-03-31
Director of Finance/CFO 47 20-05-31
Chief Tech/Sci/R&D Officer 50 20-04-30
Members of the board TitleAgeSince
Director/Board Member 58 20-05-31
Chairman 57 18-05-31
Director/Board Member 52 18-05-31
More insiders
Date Price Change Volume
24-03-28 13.64 +3.57% 489 885
24-03-27 13.17 +6.64% 595,799
24-03-26 12.35 +8.81% 378,813
24-03-25 11.35 +1.43% 178,911
24-03-22 11.19 -1.84% 128,097

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. The Company's pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, EOS-448, also known as GSK4428859A, is an antagonist of T-cell immunoreceptor with lg and ITIM domains, an immune checkpoint with multiple mechanisms of action. The Company is also advancing inupadenant, a next generation adenosine A2A receptor antagonist tailored to overcome the specific adenosine-mediated immunosuppression. It is investigating inupadenant in an open-label multi-arm Phase I/IIa clinical trial in adult cancer patients with advanced solid tumors.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
13.17 USD
Average target price
34.4 USD
Spread / Average Target
+161.20%
Consensus
  1. Stock
  2. Equities
  3. Stock iTeos Therapeutics, Inc. - Nasdaq